Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CH Biotech R&D CoTPE:6534 +0.22%86 Debt-to-Equity is 0.33 as of Jun. 2026, which is 23% below its 10-year median of 0.43. GuruFocus rates TPE:6534 with a GF Score™ of 86/100 and a GF Value™ of NT$99.26 (Fairly Valued). The stock has 3 warning signs investors should review. Among 230 Agriculture companies, CH Biotech R&D Co ranks better than 53.48% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for CH Biotech R&D Co's Debt-to-Equity or its related term are showing as below:
TPE:6534'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.23 Med: 0.43 Max: 1.06
Current: 0.33
During the past 13 years, the highest Debt-to-Equity Ratio of CH Biotech R&D Co was 1.06. The lowest was 0.23. And the median was 0.43.
TPE:6534's Debt-to-Equity is ranked better than 53.48% of 230
companies
in the Agriculture industry
Industry Median: 0.365
vs TPE:6534: 0.33
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
CH Biotech R&D Co Debt-to-Equity Related Terms
CH Biotech R&D Co Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for CH Biotech R&D Co's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6534 vs CTVA, CF, MOS: Debt-to-Equity Comparison
For the Agricultural Inputs subindustry, CH Biotech R&D Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CH Biotech R&D Co Debt-to-Equity vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, CH Biotech R&D Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where CH Biotech R&D Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CH Biotech R&D Co (TPE:6534) has a Debt-to-Equity of 0.33 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CH Biotech R&D Co and its competitors. This is 23% below median its historical median of 0.43. Over the past decade, CH Biotech R&D Co's Debt-to-Equity has ranged from 0.23 to 1.06. According to the industry distribution chart, CH Biotech R&D Co ranks #107 out of 230 companies in the Agriculture industry, placing it in the top 46.5%.
Is CH Biotech R&D Co's Debt-to-Equity too high?
CH Biotech R&D Co's current Debt-to-Equity of 0.33 is 23% below median its 10-year median of 0.43. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 1.06. The Agriculture industry median Debt-to-Equity is 0.37. CH Biotech R&D Co's value of 0.33 is 9.6% below this industry median. Based on the distribution chart, CH Biotech R&D Co ranks #107 out of 230 companies in the Agriculture industry, which is above the industry midpoint. Overall, CH Biotech R&D Co has a GF Score™ of 86/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's Debt-to-Equity compare to CTVA and CF?
According to the Agriculture industry distribution chart, CH Biotech R&D Co ranks #107 out of 230 companies for Debt-to-Equity. This puts CH Biotech R&D Co in the upper half of its industry. The industry median Debt-to-Equity is 0.37. CH Biotech R&D Co's value of 0.33 is 9.6% below this benchmark. Historically, CH Biotech R&D Co's own Debt-to-Equity has ranged from 0.23 to 1.06 over the past decade. While the company's 10-year median is 0.43 vs. the industry median of 0.37, CH Biotech R&D Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for an Agriculture company?
The median Debt-to-Equity among Agriculture companies is 0.37, based on 230 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CH Biotech R&D Co's current Debt-to-Equity of 0.33 is 9.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on CH Biotech R&D Co and its competitors. For the Agriculture industry, the median Debt-to-Equity is 0.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CH Biotech R&D Co's current Debt-to-Equity is 0.33, which is 23% below median its own 10-year median of 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Fairly Valued. The stock's GF Value™ is NT$99.26, compared to a current price of NT$92.50 — trading 6.8% below its estimated fair value. The current Debt-to-Equity is 0.33, which is 23% below median its 10-year median of 0.43 and 9.6% below the Agriculture industry median of 0.37. CH Biotech R&D Co's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current Debt-to-Equity is 0.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?
Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued.
The current stock price of NT$92.50 is trading 6.8% below its estimated GF Value™ of NT$99.26.
GuruFocus considers CH Biotech R&D Co to be Fairly Valued.
Key valuation signals for TPE:6534:
Debt-to-Equity: 0.33 (23% below median its 10-year median of 0.43)
GF Value™: NT$99.26 vs. price of NT$92.50 (6.8% below fair value)
Industry Position: 9.6% below the Agriculture median (#107 of 230)
No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
86GF Score
Get the complete analysis for TPE:6534
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6534 has been successfully added to your 
